Long-acting transient polymer conjugates of exendin

Patent metadata

Field	Value
Publication number	US-9353170-B2
Application number	US-66362808-A
Country	US
Kind code	B2
Filing date	Jun 5, 2008
Priority date	Jun 8, 2007
Publication date	May 31, 2016
Grant date	May 31, 2016

Abstract

Long-acting polymer exendin-4 or exendin agonist derivatives of the formula Pol-L-E are provided wherein Pol is a polymer, L is a releasing linker undergoing slow autohydrolysis and E is an exendin or exendin agonist. These exendin or exendin agonists are slowly released from Pol-L upon administration to a living organism. The derivatives are useful e.g. for the treatment of diabetes mellitus.

First claim

The invention claimed is:

1. A polymeric compound of the general formula (I)
Pol-L-E  (I)

wherein Pol is a polymer,
wherein L is a releasing linker capable of undergoing autohydrolysis and is a non-biologically active linker moiety -L 1 represented by formula (Ia),

wherein the dashed line indicates attachment to a nitrogen atom of a biologically active moiety by forming an amide bond,
wherein R is substituted with one group L 2 -Pol,
wherein L 2 is a single chemical bond or a spacer,
wherein E is exendin or an exendin agonist,
and wherein the bond between L and E is hydrolysed under in vivo conditions at a pH-value between 7.0 and 7.5 at a temperature of 36° to 38° C. in human plasma with a half-life of 24 hours or more.

2. A polymeric compound according to claim 1 , wherein Pol is a polyalkyloxy-based polymers, L is a releasing linker consisting of neighbouring groups catalyzing hydrolysis of a transient linkage and E is exendin or an exendin agonist, wherein the bond between L and E is hydrolysed under in vivo conditions at a pH-value between 7.0 and 7.5 at a temperature of 36° C. to 38° C. in human plasma with a half-life between 24 hours and 100 days.

3. A polymeric compound according to claim 1 wherein Pol is selected from poly(propylene glycol), poly(ethylene glycol), starch, hydroxyethyl starch (HES) poly(vinyl alcohols), poly(oxazoline, poly(acrylic acids), poly(acrylamides), poly(acrylates), poly(methacrylates), poly(organophosphazenes), poly(siloxanes), poly(vinylpyrrolidone), poly(cyanoacrylates), poly(esters), poly(glutamic acid), collagen, and gelatin.

4. A polymeric compound according to claim 1 wherein Pol is a hydrogel.

5. A polymeric compound according to claim wherein Pol is a branched or hyperbranched polymer.

6. A polymeric compound according to claim wherein Pol is a biopolymer.

7. A polymeric compound according to claim wherein Pol is a protein.

8. A polymeric compound according to claim 1 wherein Pol is a linear or branched poly(ethylene glycol) with a molecular weight between 2,000 Da and 150,000 Da.

9. A polymeric compound according to claim 1 wherein Pol is a linear or branched poly(ethylene glycol) with a molecular weight between 20,000 Da and 80,000 Da.

10. A polymeric compound according to claim 1 , wherein E is an exendin or exendin agonist selected from the group consisting of
(i) exendin-4 analogues and amidated exendin-4 analogues, in which sequences one or more amino acid residues have been replaced by different amino acid residues including N-terminal modifications,
(ii) truncated exendin-4 and truncated forms that are amidated,
(iii) truncated exendin-4 and truncated forms that are amidated, in which sequences one or more amino acid residues have been replaced by different amino acid residues,
(iv) GLP-1 and amidated GLP-1,
(v) GLP-1-analogues and amidated GLP-1 analogues, in which sequences one or more amino acid residues have been replaced by different amino acid residues including N-terminal modifications,
(vi) truncated GLP-1 and truncated forms that are amidated,
(vii) truncated GLP-1 and truncated forms that are amidated, in which sequences one or more amino acid residues have been replaced by different amino acid residues; and
(viii) AVE-0010(ZP-10), BAY-73-7977, TH-0318, BIM-51077, NN-2211 and LY315902.

11. A polymeric compound according to claim 1 , wherein E is an exendin or an exendin agonist of SEQ ID No 1 to SEQ ID No 20.

12. A polymeric compound according to claim 1 , wherein E is exendin-3 having SEQ ID No 2 or exendin-4 having SEQ ID No 1.

13. A pharmaceutical composition comprising at least one polymeric compound according to claim 1 together with a pharmaceutically acceptable carrier which is useful in a medicine.

Assignees

• Hersel Ulrich
• Rau Harald
• Vetter Dirk
• Wegge Thomas
• Sanofi Aventis Deutschland

Inventors

• Hersel Ulrich
• Rau Harald
• Vetter Dirk
• Wegge Thomas

Classifications

• A61P5/50

  for increasing or potentiating the activity of insulin · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61K47/61

  the organic macromolecular compound being a polysaccharide or a derivative thereof · CPC title

• A61K47/65

  Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers · CPC title

• A61K47/643

  Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL] · CPC title